Trust is Earned

over
300,000 Patients Treated

20 Years
of Experience

In clinical trials, registries, and site-reported use, the GORE® EXCLUDER® AAA Device has ***proven*** to be a safe, effective, and durable solution, earning the trust of physicians worldwide. It is also the ***most studied**** of the currently available endografts, and the U.S. ***market leader*** for EVAR devices.

Contact your local *Sales Associate* for more information.

* Based on company-sponsored trials and registries shown on clinicaltrials.gov for currently available stent grafts

GORE EXCLUDER®
AAA ENDOPROSTHESIS

GORE® EXCLUDER® AAA Device Clinical Trial and Registry Data

	Low Permeability Post-Approval Study	Global Registry for Endovascular Aortic Treatment (GREAT)	GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE) 12-04 Study
Enrollment	2005–2006	2010–2016	2013–2015
Length of follow-up (through)	2 years	3 years	1 year
Number of patients possible	139	3,273	63
Freedom from aneurysm-related mortality	100.0%	98.5%	100.0%
Freedom from reintervention	87.1%	93.4%	93.7%
Freedom from aneurysm enlargement (≥ 5 mm)	95.9%	92.0%	95.7%[1]
Conversion to open	0.7%	0.4%	0.0%
Aneurysm-related rupture	0.0%	0.2%	0.0%
Migration	2.4%	0.0%	0.0%
Type I Endoleak	0.7%	1.2%	0.0%
Type III Endoleak	0.7%	0.2%	0.0%
Limb occlusion	0.7%	0.5%	0.0%[2]

To calculate the overall event rates from procedure through end of study period, all subjects who could have had events, regardless of length of follow-up, were included. For outcome data, GREAT only collects site-reported serious adverse events.

1. For patients presenting with pre-existing AAA, defined as abdominal aorta >50 mm, evaluated by Core Lab.
2. Patency of the common and external iliac arteries on the non-IBE treatment side.

INDICATIONS FOR USE: Trunk-Ipsilateral Leg Endoprosthesis and Contralateral Leg Endoprosthesis Components. The GORE® EXCLUDER® AAA Endoprosthesis is intended to exclude the aneurysm from the blood circulation in patients diagnosed with infrarenal abdominal aortic aneurysm (AAA) disease and who have appropriate anatomy as described below: Adequate iliac / femoral access; Infrarenal aortic neck treatment diameter range of 19–32 mm and a minimum aortic neck length of 15 mm; Proximal aortic neck angulation ≤ 60°; Iliac artery treatment diameter range of 8–25 mm and iliac distal vessel seal zone length of at least 10 mm. **Aortic Extender Endoprosthesis and Iliac Extender Endoprosthesis Components.** The Aortic and Iliac Extender Endoprostheses are intended to be used after deployment of the GORE® EXCLUDER® AAA Endoprosthesis. These extensions are intended to be used when additional length and / or sealing for aneurysmal exclusion is desired. **CONTRAINDICATIONS:** The GORE® EXCLUDER® AAA Endoprosthesis is contraindicated in patients with known sensitivities or allergies to the device materials and patients with a systemic infection who may be at increased risk of endovascular graft infection. Refer to *Instructions for Use* at goremedical.com for a complete description of all warnings, precautions and adverse events. Rx_{Only}

GORE
Creative Technologies Worldwide

W. L. Gore & Associates, Inc.
Flagstaff, AZ 86004

+65.67332882 (Asia Pacific)
00800.6334.4673 (Europe)
800.437.8181 (United States)
928.779.2771 (United States)

goremedical.com

Products listed may not be available in all markets.